Compare Teucrium Soybean Fund (SOYB) vs 10X Genomics Inc (TXG) Price & Performance

SOYB trades at $25.88, up 1.53% today, with a bullish technical outlook supported by moving averages. The stock shows strong momentum indicators but lacks available financial ratio data. Recent news highlights potential tailwinds from China's $17 billion U.S. crop purchase pledge through 2028, which may benefit agricultural sector stocks.

The stock's outlook is cautiously optimistic due to positive technical signals and favorable sector news, but investment is tempered by absent fundamental metrics and reliance on broader agricultural market trends. Key risks include commodity price volatility and execution uncertainties in trade agreements.

TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.

The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.